Cara Therapeutics (CARA) Misses Q4 EPS by 33c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.81), $0.33 worse than the analyst estimate of ($0.48). "The Company did not recognize any revenues during the fourth quarter of 2016 or 2015."

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Is the global equity rally broadening? UBS weighs in